LOX Systemic Inhibitor

LOX Systemic Inhibitor - myelofibrosis and pancreatic cancer

Pharmaxis has developed an oral drug inhibiting all lysyl oxidase family members with potential anti-fibrotic application in severe fibrotic indications. This compound has positive results in in vivo models of myelofibrosis and pancreatic cancer and additional confirmatory studies are being run at the present time. The 28 day tox studies required to commence phase 1 clinical trials have been satisfactorily completed, with the objective of commencing phase 1 studies in the first half of 2019.

Access Pharmaxis Publications and Posters on LOX inhibitors